Craig-Hallum initiated coverage of Phathom Pharmaceuticals with a Buy rating and $21 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PHAT:
- Phathom Pharmaceuticals price target lowered to $30 from $35 at BMO Capital
- Phathom Pharmaceuticals expects cash to fund operations through 2024
- Phathom Pharmaceuticals reports Q4 EPS ($1.33), consensus ($1.35)
- Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- PHAT Nosedives on Vonoprazan Uncertainties